Importantly, our findings demonstrate for the first time that DCLK1 directly activates RAS and that DCLK1-targeted monoclonal antibodies can be used to inhibit PDAC tumor growth in xenografts and the KPC mouse model. The gene discussed is DCLK1; the disease is neoplasm.